Previous Article | Next Article 
Molecular and Cellular Biology, January 2001, p. 61-72, Vol. 21, No. 1
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.1.61-72.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Activation of NF-
B by Double-Stranded RNA
(dsRNA) in the Absence of Protein Kinase R and RNase L Demonstrates the
Existence of Two Separate dsRNA-Triggered Antiviral Programs
Mihail S.
Iordanov,1
John
Wong,1
John C.
Bell,2,3 and
Bruce E.
Magun1,*
Department of Cell and Developmental Biology,
Oregon Health Sciences University, Portland, Oregon
97201,1 and Ottawa Regional Cancer
Center Research Laboratories, Ottawa, Ontario K1H
8L6,2 and Department of
Biochemistry, University of Ottawa, Ottawa, Ontario K1H
8M5,3 Canada
Received 27 June 2000/Returned for modification 8 August
2000/Accepted 22 September 2000
 |
ABSTRACT |
Double-stranded RNA (dsRNA) of viral origin triggers two programs
of the innate immunity in virus-infected cells. One is intended to
decrease the rate of host cell protein synthesis and thus to prevent
viral replication. This program is mediated by protein kinase R (PKR)
and by RNase L and contributes, eventually, to the self-elimination of
the infected cell via apoptosis. The second program is responsible for
the production of antiviral (type I) interferons and other alarmone
cytokines and serves the purpose of preparing naive cells for the viral
invasion. This second program requires the survival of the infected
cell and depends on the expression of antiapoptotic genes through the
activation of the NF-
B transcription factor. The second program
therefore relies on ongoing transcription and translation. It has been
proposed that PKR plays an essential role in the activation of NF-
B
by dsRNA. Here we present evidence that the dsRNA-induced NF-
B
activity and the expression of beta interferon and inflammatory
cytokines do not require either PKR or RNase L. Our results indicate,
therefore, that the two dsRNA-activated programs are separate and can
function independently of each other.
 |
INTRODUCTION |
At the cellular level, the innate
immune response to viruses relies on the execution of two apparently
conflicting cellular programs: cell suicide (apoptosis) and survival.
The first program is probably most efficient for viral infections that
are initiated by a small number of infected cells at a local site of
virus entry. In such case, it seems beneficial (for the organism) for
this first population of infected cells to undergo a rapid process of
self-elimination through apoptosis, thus preventing further infection.
That this first line of antiviral defense is widely used is evident
from the multitude of antiapoptotic strategies employed by viruses.
Viral genomes encode a growing number of apoptosis-inhibiting proteins,
such as the adenovirus E1B protein (45, 72), the
baculovirus p35 protein (5, 44, 58), the cowpox virus CrmA
protein (17, 63), the poxvirus and gammaherpesvirus v-FLIP
proteins (66), and others (for a review, see reference 62). Genetic evidence from mice (48)
(see below) demonstrates that inhibition of apoptosis by the virus is
critical for the virulence of encephalomyocarditis virus (EMCV), a
picornavirus that is lethal to infected mice.
A common viral intermediate that is recognized by specific cellular
sensory systems to trigger apoptosis is viral double-stranded RNA
(dsRNA). The best-characterized effect of dsRNA on cells is the
inhibition of protein synthesis in host cells. The cellular dsRNA-detecting systems that are responsible for the translational inhibition in response to viral infection are the dsRNA-activated protein kinase (PKR) and the coupled 2-5 oligoadenylate
synthase/RNase L system. PKR (39) is a dormant enzyme
directly activated by binding of dsRNA (for recent reviews, see
references 28 and 73). A major
substrate of PKR is the
-subunit of the eukaryotic translation
initiation factor 2 (eIF-2
) (22, 35). Phosphorylation of eIF-2
greatly reduces the rate of initiation of translation (50). The 2-5 oligoadenylate synthase/RNase L system is
composed of a family of dsRNA-dependent enzymes known as 2'-5'
oligoadenylate synthetases (OAS) (7, 24, 43) and the
dormant cytosolic RNase L (82). Upon dsRNA binding, OAS
produce unusual second messengers, short 2'-5'-linked oligoadenylates
(2-5A), which, in turn, specifically bind to and activate RNase L
(41). Activated RNase L cleaves diverse RNA substrates,
including 18S and 28S rRNA, thus inhibiting cellular protein synthesis
(26, 51, 52, 74). Fibroblasts from mice nullizygous for
both PKR and RNase L alleles are unable to inhibit protein synthesis
when challenged with dsRNA (26), thus demonstrating that
these two enzymes are both required and sufficient for the
translational inhibition caused by dsRNA. Recently, both PKR (2,
3, 15, 20, 34, 53, 77) and RNase L (7-9, 13, 83,
85) have been found to mediate dsRNA-induced apoptosis. The
mechanisms of involvement of PKR and RNase L in the dsRNA-triggered
apoptosis are, however, poorly understood. Considering the role of both
PKR and RNase L in inhibiting protein synthesis, one obvious candidate
for a death-inducing signal is the impaired process of translation. A
sustained inhibition of protein synthesis is sufficient to trigger apoptosis in cells in a way that is independent of the particular means
of achieving translational inhibition (27). However, other (more direct) mechanisms of dsRNA-induced cell death, which are independent of the state of cellular translation, are very likely to exist.
The second dsRNA-initiated program for antiviral defense involves the
production and secretion by the infected cells of alarmone cytokines,
the best-studied examples of which are the alpha, beta, and omega
interferons, [for reviews, see references 16 and
54]). The importance of these interferons for
conferring viral resistance to naive cells has been demonstrated by the
strong sensitivity to viral infections of mice lacking the common
subunit of the alpha, beta, and omega interferon receptor
(40). It is thought that these interferons exert their
pleiotropic antiviral actions by preparing cells to interfere with
multiple, virus-specific steps of the viral replication cycle,
including viral entry, uncoating, transcription, RNA stability,
maturation, assembly, and release (for a review, see reference
54). Interferons are also important for the ability
of adaptive immunity to take over the innate immune response in
combating the virus. For instance, mice lacking the interferon alpha,
beta, and omega receptor are unable to mount a cytotoxic T-lymphocyte
response to infection with lymphocytic choriomeningitis virus
(40).
A crucial step in the virus-induced beta interferon production appears
to be its transcriptional upregulation by viral dsRNA (for a review,
see reference 37). The highly specific
transcriptional induction of the beta interferon gene by viruses has
been best studied for the human beta interferon gene promoter/enhancer
region. This region contains a set of regulatory elements called
positive regulatory domains (PRDI to PRDIV). PRDII, PRDI-III, and PRDIV bind the transcription factors NF-
B, IRF-1 (or IRF-3), and
ATF-2/c-Jun, respectively (for a review, see reference
37). Importantly, NF-
B appears to be absolutely
required for the virus-induced activation of the human beta interferon
promoter (18, 64, 65).
For the second (interferon-dependent) program of innate antiviral
immune response to be successful, the proapoptotic response of the
infected cells must be suppressed, at least for the time required to
complete the production and secretion of alarmone cytokines.
Interestingly, genetic evidence strongly suggests that NF-
B not only
plays an important role in the production of beta interferon but also
is essential in suppressing virus-induced apoptosis. Mice engineered to
lack the p50/NF-
B1 subunit of NF-
B (see below) are resistant to
infection with EMCV (48, 49). This surprising result
(which seems to contradict the important role of NF-
B in combating
viral infections) is explained by the discovery that EMCV-infected
cells from p50/NF-
B1-nullizygous mice (as well as from mice
engineered to lack the other common subunit of NF-
B, p65/RelA [see
below]) undergo very rapid apoptosis before the virus could reproduce
(48). These results demonstrate the apoptosis-suppressing
function of NF-
B in EMCV infection. The antiapoptotic role of
NF-
B is thought to result from the NF-
B-dependent transcriptional
activation of several apoptosis-inhibiting genes, such as the genes
encoding the inhibitor-of-apoptosis proteins (IAPs; for a review, see
reference 32) IAP-1, IAP-2, and X-linked IAP
(X-IAP1) (12, 55, 70), Bcl-XL (10, 33,
68), and A1/Bfl1 (33, 57, 69, 86).
How is NF-
B activated in general and by viruses and dsRNA in
particular? NF-
B is a collective name for a group of homo- and
heterodimeric transcriptional regulators (activators or repressors) consisting in vertebrates, of the polypeptide products of the p50/p105(nfkb1),
p52/p100(nfkb2), c-rel,
relA, and relB genes (for reviews, see references
21 and 42). In mammalian cells, the most common NF-
B complex is the p50/NF-
B1-p65/RelA
heterodimer, and it is this combination that is most commonly referred
to as NF-
B proper (42). An essential role in the
regulation of NF-
B is played by a family of inhibitory proteins,
collectively termed I
Bs (the family encompasses I
B-
,
I
B-
, I
B-
, and Bcl-3 [for a review, see reference
31]). In nonstimulated cells, I
Bs sequester the
p50/NF-
B1-p65/RelA heterodimer in the cytoplasm, thus preventing it
from localizing in the nucleus and stimulating the transcription of
NF-
B-dependent genes (for a review, see reference
31). With the notable exception of UV radiation, a
potent NF-
B activator, most stimuli that activate NF-
B (including
viruses and dsRNA) cause the phosphorylation of serine residues 32 and
36 in I
B-
(and of the corresponding serine residues in
I
B-
). The phosphorylation of I
B causes its rapid
polyubiquitinylation and degradation by the 26S proteasome, thus
releasing NF-
B and allowing it to translocate to the nucleus (most
extensively reviewed in references 30, 31, and
80). A multicomponent I
B kinase (IKK) complex has been purified, molecularly cloned, and found to consist of two homologous catalytic subunits (IKK1/
and IKK2/
) (14, 38, 81) and a noncatalytic subunit (IKK
, also known as NEMO)
(75). Genetic inactivation of IKK in mice demonstrated
that IKK2/
and IKK
(but not IKK1/
) are required for the I
B
phosphorylation and subsequent NF-
B activation in response to most
agents (25, 36, 46, 59, 61). Due to the lack of suitable
targeted gene inactivation models, however, the modes of upstream
regulation of IKK activity are currently completely unknown, even
though several kinases have been proposed to act upstream of IKKs. For instance, in striking contrast to all experimental evidence concerning the role of PKR in triggering the protein synthesis-inhibiting and
proapoptotic program of antiviral innate immunity, this kinase has been
proposed to be a major mediator of virus- and dsRNA-induced activation
of NF-
B. Using mouse embryonic fibroblasts (MEF) and 3T3-like
fibroblast cell lines from one of the two published PKR genetic
knockouts (76), several groups found these cells to be
deficient in dsRNA-induced NF-
B activation, thus postulating an
important role for this kinase in activating NF-
B in response to
viruses (11, 19, 79).
We considered that this postulated role of PKR in dsRNA-induced NF-
B
activation ultimately imposes the paradoxical situation that the same
dsRNA-sensing molecule (PKR) would trigger the execution of the two
opposing antiviral programs in the same cell: the program that attempts
to eliminate the infected cell through translational inhibition and
apoptosis and the program that attempts to suppress apoptosis through
NF-
B activation. To resolve this paradox, we have employed a panel
of primary MEF or 3T3-like cell lines from two independent successful
attempts to inactivate the PKR gene in mice (1, 76), from
the RNase L-deficient mice (83), and from mice with a
double deficiency in both the PKR and the RNase L genes (26,
84). Our study demonstrates that neither PKR nor RNase L is
required for the activation of NF-
B by dsRNA or EMCV. Furthermore,
we found that the ability of dsRNA to stimulate the expression of beta
interferon and of the inflammatory cytokines interleukin-6 (IL-6) and
tumor necrosis factor alpha (TNF-
) was also independent of the
presence of PKR. Thus, the "translational inhibition/pro-apoptotic
program" and the "biosynthetic/anti-apoptotic program," each
triggered by viral dsRNA, appear to be mechanistically separate and to
function independently of one another.
 |
MATERIALS AND METHODS |
Chemicals.
Lipofectin reagent was from Gibco BRL/Life
Technologies. pI-pC was from Midland Certified Reagent Co. and was
stored at
20°C as a 10-mg/ml stock solution in double-distilled
deionized water. The proteasome inhibitors
benzyloxycarbonylleucyl-leucyl-leucine aldehyde (MG 132) and
benzyloxycarbonyliso-leucyl-glutamyl(OtBu)-alanyl-leucine aldehyde
(proteasome inhibitor I) were purchased both from Alexis Biochemicals
and from Calbiochem, and there was no detectable difference in their
activities. Recombinant human TNF-
was from R&D Systems. All
radiochemicals were from DuPont NEN Research Products.
Cells.
All cells were maintained in Dulbecco's modified
Eagle's medium (DMEM) supplemented with 10% calf serum (HyClone,
Logan, Ut.). pkr+/+ (EX12) and
pkr0/0(EX12) MEF have been described
previously (1) and were referred to there as
pkr+/+ and pkr0/0 cells.
pkr+/+(EX2+3) and
pkr0/0(EX2+3) MEF were described
previously (76) and were also referred to there as
pkr+/+ and pkr0/0 cells. The
rnasel+/+/pkr+/+,
rnasel
/
/pkr+/+, and
rnasel
/
/pkr
/
3T3-like
fibroblasts were described previously (84) and are referred to here by the same names as in reference
26.
Lipofectin-mediated delivery of pI-pC.
The procedure for
treatment of cells with pI-pC was the same as described in reference
26. For each milliliter of final volume of
Lipofectin mixture, an initial concentrated mixture (containing
Lipofectin and pI-pC) was prepared in one-quarter of the final volume
(250 µl). To this end, 10 µl of Lipofectin (1 mg/ml) was added to
serum- and antibiotic-free DMEM and mixed, and the desired amount of
pI-pC was added (in a volume of 250 µl). This mixture was left for 10 min at room temperature. Finally, the remaining three-quarters of the
final volume (750 µl) was added. Before the application of the
Lipofectin-pI-pC mixtures, the cells were washed once with serum-free DMEM.
Preparation of cell lysates for immunoblot analysis.
To
avoid any possible dephosphorylation or proteolytic degradation of the
proteins of interest, the cells were typically harvested by aspirating
the cell culture medium, scraping the cells directly on the tissue
culture plate in 2× sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) sample-loading buffer, and subjecting them
to heat denaturation at 95°C for 5 min. Cell lysates were stored at
70°C.
Antibodies and immunoblot analyses.
The antibodies against
I
B-
(C-20), phospho-(serine-32)-I
B-
(B-9), PKR (M-515 and
D-20), and p65/RelA (C-20) and the blocking peptide solutions used in
the experiment in Fig. 3 (p65/RelA C-20 peptide and MEKK1 C-22 peptide)
were from Santa Cruz Biotechnologies. For the antibody blocking, 1 volume of the anti-p65/RelA antibody was preincubated with 5 volumes of
the respective blocking peptide solution for 6 h at room
temperature. The antibody against I
B-
(13996E) was from
Pharmingen. The antibodies against the dually phosphorylated forms of
JNK and p38
mitogen-activated protein (MAP) kinase were from New
England BioLabs. The antibody against the phosphorylated form of
eIF-2
was from Research Genetics. The electrophoretic separation of
proteins in SDS-PAGE and electrotransfer to a polyvinylidene difluoride
membrane (Millipore) were performed using standard procedures.
Immunoprobing with specific antibodies and enhanced chemiluminescence
detection (DuPont NEN Research Products) were performed as
specified by the respective manufacturers.
Immunocytochemical staining of p65/RelA.
Cells were grown on
Thermanox coverslips (Nunc). After the appropriate treatments, the
cells were fixed in cold (
20°C) methanol for 5 min, dried, and
stored at
20°C. Blocking was performed with 1.5% normal goat serum
in PBS for 1 h followed by incubation with the primary antibody
(anti-p65/RelA [C-20 from Santa Cruz] at a 1:800 dilution in PBS with
1.5% serum) for 1 h. After the cells were washed in PBS,
incubation with secondary antibody was performed with biotinylated
anti-rabbit immunoglobulin G (1:500 dilution in PBS with 1.5% serum)
for 1 h, followed again by washing. Endogenous peroxidase activity
was quenched with 2% hydrogen peroxide in PBS for 30 min. After being
washed, the cells were incubated with VectaStain Elite ABC reagent
(Vector Laboratories) for 1 h. Finally, the cells were washed,
incubated with diaminobenzidine (Sigma) until the desired stain
intensity developed, and rinsed with water. Photographs were taken
using a CoolSnap digital camera mounted on a Zeiss microscope.
EMSA.
Nuclear extracts were prepared and used in
electrophoretic mobility shift assays as described in references
4 and 56. Briefly, cells were
collected by scraping in ice-cold PBS, sedimented, and resuspended in
100 µl of lysis buffer (10 mM HEPES [pH 7.9], 1 mM EDTA, 60 mM KCl,
0.5% Nonidet P-40 [NP-40], 1 mM dithiothreitol [DTT], protease
inhibitor cocktail [Roche Molecular Biochemicals]). After 5 min on
ice, nuclei were sedimented at 1,200 × g for 5 min.
The supernatant was used as the cytoplasmic extract. The nuclei were
washed with lysis buffer without NP-40 and suspended in 100 µl of
nuclear buffer (250 mM Tris-HCl [pH 7.8], 60 mM KCl, 1 mM DTT,
protease inhibitor cocktail). Nuclei were lysed by three cycles of
freezing and thawing in liquid nitrogen and ice. The nuclear extracts
were cleared by centrifugation at 13,000 × g for 15 min. EMSAs were done as described in reference 4:
the binding reaction was performed in a volume of 20 µl with 5 µg of nuclear protein in a buffer containing 12 mM HEPES (pH 7.8), 62.5 mM
Tris-HCl (pH 7.8), 60 mM KCl, 0.6 mM EDTA, 12% glycerol, 5 mM DTT, 2 µg of bovine serum albumin, and 1 µg of poly(dI-dC). 32P-radiolabeled consensus double-stranded NF-
B-binding
oligonucleotide (5'-AGT TGA GGG GAC TTT CCC AGG C-3')
or the corresponding oligonucleotide with a single-base point
mutation (5'-AGT TGA GGC GAC TTT CCC AGG C-3')
from Santa Cruz Biotechnologies were used as probes. For the
competition experiments, a consensus double-stranded p53-binding
oligonucleotide (5'-TAC AGA ACA TGT CTA AGC ATG CTG GGG-3')
from Santa Cruz Biotechnologies was used as a nonspecific competitor.
RNA isolation and Northern blot detection of mRNA.
Total
cellular-RNA was isolated using TRIzol reagent (GIBCO BRL) as specified
by the manufacturer. The multiprobe detection of beta interferon, IL-6,
and TNF-
was performed using a RiboQuant RNase protection assay kit
with a mCK-3b multiprobe template (Pharmingen) as specified by the
manufacturer. A 10-µg portion of total RNA was used.
Determination of IL-6 production.
The production of IL-6 was
determined quantitatively using the Quantikine M mouse IL-6
enzyme-linked immunosorbent assay (R&D Systems) as specified by the
manufacturer and as described previously (26).
 |
RESULTS |
EMCV infection causes the proteolytic degradation of
I
B-
in both pkr+/+ and
pkr0/0 MEF.
To investigate the possible
role of PKR in virus-induced activation of NF-
B, we employed primary
fibroblasts derived from wild-type (pkr+/+) or
pkr0/0 mouse embryos established in the
laboratory of one of us (1). Since the inactivation of PKR
alleles in these mice was achieved through a homologous recombination
event involving exon 12 of the PKR gene, these MEF are referred to
hereafter as pkr+/+(EX12) and
pkr0/0(EX12), respectively. Later,
when MEF from a different PKR knockout (inactivating the PKR gene exons
2 and 3) (76) are used (see below), these cell will be
referred to as pkr+/+(EX2+3) and
pkr0/0(EX2+3), respectively. At
2 h after infection with EMCV, there was a detectable decrease in
the steady-state levels of I
B-
both in the
pkr+/+(EX12) and in the
pkr0/0(EX12) MEF (Fig.
1A, lanes 3 and 7). Four hours after the
infection, I
B-
levels in both the
pkr+/+(EX12) and the
pkr0/0(EX12) MEF were reduced to a
minor fraction of those in the control cells (compare lanes 2 and 6 with lanes 4 and 8). The absence of PKR in the
pkr0/0(EX12) MEF was confirmed
using two independent PKR antisera (compare lanes 1 to 4 with lanes 5 to 8). At 4 h after the infection with EMCV, the levels of PKR in
the wild-type MEF were reduced (lane 4), probably reflecting the
overall inhibition of protein synthesis and the subsequent turnover of
PKR protein in these cells.

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 1.
(A) EMCV-induced degradation of I B- .
pkr+/+(EX12) and
pkr0/0(EX12) MEF (~2 × 106 cells) were infected, where indicated, with EMCV (100 PFU per cell) in 2 ml of serum-free medium for 1 h, after which
time the excess virus was removed by extensive washing of the cells
with serum-free medium. The cells were further incubated in serum-free
medium. At 2 or 4 h after the removal of the extracellular virus,
the mock-infected or infected cells were harvested and the cell lysates
were processed for the immunoblot detection of I B- (top panel) as
described in Materials and Methods. The membranes were stripped and
reprobed consecutively with an anti-phosphorylated p38 MAP kinase
antibody (second panel from top) and with the M-515 (third panel from
top) and D-20 (bottom panel) PKR antisera. A nonspecific band
recognized by the D-20 antibody is indicated by an asterisk. (B) Lack
of PKR activity in the pkr0/0(EX12)
MEF. pkr+/+(EX12) and
pkr0/0(EX12) MEF were left untreated
(Co) or were treated with Lipofectin (LF) alone or with pI-pC (10 µg/ml) in the presence of Lipofectin (LF + dsRNA). At 3 h
after the treatments, the phosphorylation states of eIF-2 and p38
MAP kinase were assessed in immunoblot analyses.
|
|
dsRNA triggers the phosphorylation, polyubiquitinylation, and
proteosome-mediated degradation of I
Bs in both
pkr+/+(EX12) and
pkr0/0(EX12) MEF.
The
degradation of I
B-
in EMCV-infected MEF was paralleled by the
phosphorylation of the stress-activated protein kinases (SAPK) p38
MAP kinase (Fig. 1A, lanes 3, 4, 7, and 8), JNK1, and JNK2 (not shown).
Previously, we reported that SAPK are potently activated by dsRNA
(26). We set out, therefore, to investigate the specific
role of dsRNA in virus-induced activation of NF-
B, independent of
viral proteins that, in many cases, also modulate NF-
B activity. To
achieve this goal, we used pI-pC, a synthetic dsRNA, which was
delivered into cells via lipofection (see Materials and Methods).
First, we set out to confirm that the deletion of exon 12 of PKR in the
pkr0/0(EX12) MEF resulted in a
complete abrogation of PKR activity. Treatment of
pkr+/+(EX12) MEF with pI-pC
(hereafter referred to as dsRNA) caused the phosphorylation of eIF-2
at serine-51 (Fig. 1B, lane 3). Identically treated
pkr0/0(EX12) MEF failed to display
the phosphorylation of eIF-2
at serine-51 (lane 6). In contrast to
these results and in agreement with our previous findings
(26), the p38
MAP kinase was phosphorylated in response
to dsRNA both in the PKR-containing and in the PKR-deficient cells
(lanes 3 and 6). We concluded, therefore, that the deletion of exon 12 of PKR in the pkr0/0(EX12) MEF has
resulted indeed in a complete abrogation of PKR activity.
We next addressed the dsRNA-induced signaling to NF-
B. Treatment of
either pkr+/+(EX12) or
pkr0/0(EX12) MEF with pI-pC for
1 h resulted in a detectable increase in serine-32 phosphorylation
of I
B-
as measured by immunoblot analysis using an antibody
recognizing specifically only the serine-32-phosphorylated form of
I
B-
(Fig. 2A, upper panels, lanes 2 and 4). Consistent with the role of I
B-
phosphorylation in its
degradation by the ubiquitin-proteosome system (for a review, see
reference 31), the levels of I
B-
were
significantly reduced in dsRNA-treated cells (lower panels, lanes 2 and
4). To investigate whether I
B-
is also degraded by the
ubiquitin-proteosome system in response to dsRNA, we employed two
peptide proteosome inhibitors,
benzyloxycarbonylleucyl-leucyl-leucine aldehyde (labeled LLL
in Fig. 2B) and
benzyloxycarbonyliso-leucyl-glutamyl(OtBu)-alanyl-leucine aldehyde
(labeled IEAL in Fig. 2B). Treatment of either
pkr+/+(EX12) or
pkr0/0(EX12) MEF with dsRNA for
1 h led to a detectable reduction in the steady-state levels of
I
B-
in both the
pkr+/+ (EX12) and the
pkr0/0(EX12) MEF (Fig. 2B, narrow
panels, lane 6). Pretreatment of the cells with either of the two
proteosome inhibitors prevented the dsRNA-induced degradation of
I
B-
(narrow panels, lanes 9 and 10). Furthermore, in the presence
of both dsRNA and the proteasome inhibitors, the cells accumulated
multiple anti-I
B-
-immunoreactive bands with reduced mobility in
SDS-PAGE (wide panels, lanes 9 and 10; note that the wide panels
represent a longer film exposure of the same immunoblots presented in
the narrow panels). The appearance of these novel forms of
anti-I
B-
immunoreactivity with reduced mobility is consistent
with unimpaired levels of dsRNA-induced polyubiquitinylation of
I
B-
but a blocked polyubiquitinylation-induced degradation of
I
B-
by the proteasome. Importantly, identical effects on the
I
Bs of these proteasome inhibitors were observed in cells stimulated
with TNF-
, a well-established inducer of proteasome-mediated
degradation of I
Bs (reference 67 and data not
shown). None of the dsRNA-induced effects on I
Bs (phosphorylation, polyubiquitinylation, and proteasome-dependent degradation) appeared to
require the presence of PKR. Neither single-stranded RNA (pI or pC),
nor dsDNA (p[d(IC)]) had any effect on I
B-
or I
B-
(data
not shown), indicating that the effects observed using pI-pC represent
a bona fide dsRNA response. Despite the limited ability to compare the
behavior of I
B-
and I
B-
in the same assay, the results
shown in Fig. 2 favor the conclusion that both I
Bs are addressed by
dsRNA-induced signal transduction pathways in a similar manner.

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 2.
dsRNA-triggered phosphorylation, polyubiquitinylation,
and proteosome-mediated degradation of I Bs in both
pkr+/+(EX12) and
pkr0/0(EX12) MEF. (A)
pkr+/+(EX12) and
pkr0/0(EX12) MEF were treated with
Lipofectin alone (lanes Control) or with pI-pC (10 µg/ml) in the
presence of Lipofectin (lanes dsRNA). Note that the same procedure for
Lipofectin treatment (with or without pI-pC) applies to all experiment
presented in Fig. 2 to 9 and is described in Materials and Methods. At
1 h after the treatment, the cells were harvested and processed
for immunoblot analysis of I B using either a
phospho-(Ser32)-I B -specific antibody (upper panels) or an
I B -specific antibody (lower panels). Treatment of cells with
Lipofectin does not affect I B or any other NF B-related
signaling pathway investigated in this work (data not shown). (B)
pkr+/+(EX12) and
pkr0/0(EX12) MEF were treated as in
panel A, except that, where indicated, the cells were pretreated for 25 min with benzyloxycarbonyliso-leucyl-glutamyl(OtBu)-alanyl-leucine
aldehyde (IEAL), benzyloxycarbonyl-leucyl-leucyl-leucine aldehyde
(LLL), or the respective solvents for each of them, methanol (MeOH) or
dimethyl sulfoxide (DMSO). I B steady-state levels were monitored
in an immunoblot analysis.
|
|
dsRNA-induced I
B degradation coincides with translocation of
NF-
B to the nucleus, independent of the presence or the absence of
PKR.
To investigate and determine conclusively if PKR may be
required for a functional activation of NF-
B downstream of I
B
phosphorylation and degradation, we employed
pkr+/+(EX12) and
pkr0/0(EX12) MEF and
pkr+/+ (EX2+3) and
pkr0/0(EX2+3) MEF (76).
First, we demonstrated that in the
pkr+/+(EX2+3) and
pkr0/0(EX2+3) MEF, the
Lipofectin-mediated delivery of dsRNA led to the degradation of
I
B-
and I
B-
similarly to the effect of dsRNA on the
pkr+/+(EX12) and
pkr0/0(EX12) MEF [data not shown,
but see also Fig. 8, demonstrating the dsRNA-induced I
B-
degradation in embryonic fibroblasts derived from
pkr0/0(EX2+3) × rnasel
/
mice (84)]. We then
performed immunocytochemical staining of control (Lipofectin-treated)
and dsRNA-treated MEF (EX12 and EX2+3) by using an antibody recognizing
the p65/RelA subunit of NF-
B. As shown in Fig.
3A, p65/RelA displayed a typical
cytoplasmic distribution in the control
pkr+/+(EX2+3) MEF. At 3 h after
dsRNA treatment, a strong immunopositive signal appeared in the nucleus
(Fig. 3B), indicative of induced nuclear translocation of NF-
B.
Preincubation of the antibody with a p65/RelA peptide epitope abolished
the immunocytochemical staining (Fig. 3C and D), whereas the
preincubation with an irrelevant peptide epitope had no effect on the
ability of the antibody to stain cells (Fig. 3E and 3F). An identical
pattern of nuclear staining was detected after treatment of cells with
TNF-
(data not shown). Thus, the method used in the experiment in
Fig. 3 appeared to represent faithfully the translocation of p65/RelA following a signal that triggers I
B degradation. Using this method, we next demonstrated that, both in the
pkr0/0(EX2+3) MEF and in the
pkr0/0(EX12) MEF, dsRNA led to a
nuclear translocation of p65/RelA in a manner identical to the ability
of dsRNA to cause p65/RelA nuclear translocation in the respective
wild-type cells (Fig. 4). Thus, the
evidence obtained using MEF from two independent approaches to generate
PKR-null mice demonstrates that PKR is not an essential kinase for the
migration of NF-
B to the nucleus following dsRNA-induced I
B
degradation.

View larger version (82K):
[in this window]
[in a new window]
|
FIG. 3.
dsRNA-induced nuclear translocation of NF B.
pkr+/+ (EX12) MEF were treated
with Lipofectin alone (A, C, and E) or with pI-pC (10 µg/ml) in the
presence of Lipofectin (B, D, and F). At 3 h after the treatment,
the cells were fixed and immunostained with an antibody recognizing the
p65/RelA subunit of NF B, as described in Materials and Methods. An
irrelevant peptide (representing an epitope corresponding to the
C-terminal domain of MEKK1) or a specific blocking peptide were used
(as described in Materials and Methods) in panels E and F and in panels
C and D, respectively.
|
|

View larger version (77K):
[in this window]
[in a new window]
|
FIG. 4.
dsRNA-induced nuclear translocation of NF B
independent of the presence or the absence of PKR.
pkr+/+(EX2+3),
pkr0/0(EX2+3),
pkr+/+(EX12), or
pkr0/0(EX12) MEF were treated with
Lipofectin alone (A, C, E, and G) or with pI-pC (10 µg/ml) in the
presence of Lipofectin (B, D, F, and H). At 3 h after the
treatment, the cells were fixed and immunostained with an antibody
recognizing the p65/RelA subunit of NF B as in Fig. 3.
|
|
PKR deficiency does not affect the specific DNA-binding activity of
NF-
B.
Since a fraction of PKR has been found in the nucleus
(29), it was not unreasonable to investigate whether PKR
might be involved in modulating NF-
B activity at the level of the
DNA-binding ability of this transcription factor. Nuclear extracts from
wild-type MEF (EX12) treated with either dsRNA or TNF-
displayed a
prominent DNA-binding activity in EMSA using an NF-
B-specific
oligonucleotide probe (Fig. 5, lanes 1 to
3). This DNA-binding activity was successfully competed by a 100-fold
molar excess of the same unlabeled probe (lanes 4 to 6) but was not
competed by a 100-fold molar excess of an irrelevant oligonucleotide
(lanes 7 to 9). Furthermore, the DNA-binding activity was supershifted
when the nuclear extracts were preincubated with the anti-p65/RelA
antibody (lane 10), thus leading to the positive identification of
NF-
B in the retarded protein-oligonucleotide complex. Therefore, the
EMSA appeared to be a suitable assay to study the DNA-binding activity
of NF-
B. As shown in Fig. 6A,
treatment of either pkr+/+(EX12) or
pkr0/0(EX12) MEF with dsRNA led to
the appearance in the nuclear extracts of NF-
B with similar
DNA-binding activity that did not require the presence of PKR (Fig. 6A,
compare lanes 3 and 4 with lanes 8 and 9). Furthermore, cells treated
with TNF-
displayed a similar DNA-binding activity that was
independent of PKR (lanes 5 and 10). With either dsRNA or TNF-
treatment, the induced DNA-binding activity failed to form on an
oligonucleotide probe with a single nucleotide substitution (Fig. 6A,
second panel from the bottom), further demonstrating that NF-
B is
the major (and possibly the only) DNA-binding activity in the complex.
The corresponding cytosolic extracts demonstrated the presence of PKR
only in the pkr+/+(EX12) but not
in the pkr0/0(EX12) MEF (bottom
panel).

View larger version (93K):
[in this window]
[in a new window]
|
FIG. 5.
dsRNA- and TNF- -induced specific DNA-binding activity
of NF B. pkr+/+(EX12) MEF were
treated with Lipofectin alone (lanes Co), with pI-pC (10 µg/ml) in
the presence of Lipofectin (lanes dsRNA), or with TNF- (lanes TNF).
At 3 h after either Lipofectin or dsRNA treatments or 20 min after
the TNF- treatment, the cells were harvested and nuclear extracts
were prepared as described in Materials and Methods. EMSAs were
performed as described in Materials and Methods. Where indicated, a
100-fold molar excess of either the specific NF- B-binding nonlabeled
oligonucleotide (specific competitor) or a p53-binding nonlabeled
oligonucleotide (nonspecific competitor) was added to the
binding-reaction mixtures for 10 min before the addition of the
specific 32P-labeled NF- B-binding oligonucleotide. In
the last lane, the undiluted anti-p65/RelA (C-20 from Santa Cruz)
antibody was added in 1/10 of the final reaction volume for 10 min
before the addition of the specific 32P-labeled
NF- B-binding oligonucleotide. Addition of several irrelevant
antibodies did not interfere with the specific binding of NF- B to
DNA, demonstrating the specificity of the anti-p65/RelA
antibody-induced supershift (data not shown).
|
|

View larger version (74K):
[in this window]
[in a new window]
|
FIG. 6.
dsRNA-induced specific DNA-binding activity of NF B
independent of the presence or the absence of PKR. (A)
pkr+/+(EX12) or
pkr0/0(EX12) MEF were treated with
Lipofectin alone (lanes Control), with pI-pC (10 µg/ml) in the
presence of Lipofectin (lanes dsRNA), or with TNF- (lanes TNF). At
the indicated times after the treatment, the cells were harvested and
EMSAs were performed as in the experiment in Fig. 5. A specific
32P-labeled NF- B-binding oligonucleotide (top panel) or
32P-labeled oligonucleotide bearing a single-base
substitution (Santa Cruz) (middle panel) was used. The asterisk depicts
the position in the middle panel that corresponds to the position of
the NF- B-DNA complex in the upper panel. The corresponding cytosolic
extracts (see Materials and Methods) were used in an immunoblot
procedure to demonstrate the absence of PKR in the
pkr0/0(EX12) MEF (bottom panel). (B)
pkr+/+(EX12) or
pkr0/0(EX12) MEF were left untreated
(lanes Control) or were treated with pI-pC (100 or 500 µg/ml) in the
absence of Lipofectin (lanes dsRNA), with Lipofectin alone (lane LF),
or with pI-pC (10 µg/ml) in the presence of Lipofectin (lane
LF+dsRNA). At the indicated times after the treatment, the cells were
harvested and EMSAs were performed as in the experiment in Fig. 5.
|
|
The results presented in Fig. 2 to 6A contrast with the findings of
others (11, 76, 79), who reported that fibroblasts deficient in PKR failed to respond to dsRNA with NF-
B activation. To
investigate whether the different modes of dsRNA delivery used by us
and by others are responsible for these differences, we compared the
responses of MEF either to 10 µg of pI-pC per ml in the presence of
Lipofectin or to 100 or 500 µg of pI-pC per ml without Lipofectin (as
used by Zamanian-Daryoush et al. 79). Using the
EMSA, we observed that both in the presence and in the absence of
Lipofectin, dsRNA was able to induce the NF-
B DNA-binding activity
in the PKR-containing and in the PKR-deficient cells (Fig. 6B).
The dsRNA-induced accumulation of the mRNA for beta interferon
occurs in the absence of PKR.
Previously, Yang et al.
(76) and Chu et al. (11) found that dsRNA
(applied without the aid of a lipophilic internalization vehicle) was
severely impaired in its ability to induce beta interferon expression
in the pkr0/0(EX2+3) MEF
(76) or in a
pkr0/0(EX2+3) 3T3-like fibroblast
cell line (11). We investigated whether PKR might be
required for the dsRNA-induced expression of beta interferon when dsRNA
was delivered with the aid of Lipofectin. Treatment with dsRNA for
4 h led to the accumulation of the mRNA for beta interferon (as
measured in an RNase protection assay) in the
pkr+/+(EX2+3),
pkr0/0(EX2+3),
pkr+/+(EX12), and
pkr0/0(EX12) MEF (Fig.
7A, lanes 3, 6, 9, and 12). Determination
of the actual fold activation was impossible due to the undetectable levels of beta interferon mRNA expression in the control cells (lanes
1, 4, 7, and 10). Similar to beta interferon, the mRNAs for two
inflammatory cytokines, IL-6 and TNF-
, were also induced by dsRNA in
the pkr+/+(EX2+3),
pkr0/0(EX2+3),
pkr+/+(EX12), and
pkr0/0(EX12) MEF (lanes 3, 6, 9, and
12). In contrast, the mRNAs encoding the cytokines transforming growth
factor
3 (TGF-
3) and migration inhibitory factor (MIF) were
expressed constitutively in the MEF and were not induced by dsRNA,
demonstrating the specificity of the dsRNA response (lanes 3, 6, 9, and
12). None of these mRNAs was induced by Lipofectin alone (lanes 2, 5, 8, and 11). We concluded, therefore, that PKR was not required for the
dsRNA-induced expression of beta interferon mRNA or of IL-6 and TNF-
mRNAs. PKR was also not required for the dsRNA-induced accumulation of
the mRNA for the NF-
B-dependent antiapoptotic gene iap-2
(data not shown).

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 7.
Expression of dsRNA-induced genes independent of the
presence or absence of PKR. (A) MEF with the indicated genotype were
left untreated (lanes Control) or were treated with Lipofectin alone
(lanes LF) or with pI-pC (10 µg/ml) in the presence of Lipofectin
(lanes dsRNA). At 4 h later, the cells were harvested, total RNA
was prepared, and the steady-state levels of expression of multiple
cytokines were assessed in a multiprobe RNase protection assay as
described in Materials and Methods. The levels of the mRNAs for the
ribosomal protein L32 and the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as controls
for RNA amount and loading. TGF 3, transforming growth factor 3;
MIF, migration inhibitory factor. (B) MEF with the indicated genotype
were treated with Lipofectin alone ( ) or with pI-pC (10 µg/ml;
dsRNA) in the presence of Lipofectin (+). At 24 h later, the
presence of IL-6 in the conditioned culture medium was determined as
described in Materials and Methods. Error bars represent standard
deviation from experimental points in triplicate.
|
|
PKR contributes, in mouse fibroblasts, about 50% of the overall
inhibition of translation in response to dsRNA (the other 50% being
contributed by the 2-5 oligoadenylate synthase/RNase L system)
(26). It was therefore reasonable to speculate that activated PKR may negatively affect gene expression via its inhibitory action on protein synthesis. To address this question, we employed a
highly sensitive enzyme-linked immunosorbent assay for the detection of
IL-6 and determined whether the presence or absence of PKR affects the
expression and/or secretion of this cytokine. As shown in Fig. 7B, the
levels of IL-6 in the culture medium were markedly elevated 24 h
after the treatment with dsRNA in the
pkr+/+(EX2+3),
pkr0/0(EX2+3),
pkr+/+(EX12), and
pkr0/0(EX12) MEF. We were unable,
therefore, to discern a clear pattern of PKR involvement in the
production of IL-6 in response to dsRNA.
The dsRNA-induced activation of NF-
B does not require RNase
L.
The OAS/2-5A/RNase L system is a dsRNA-activated signal
transduction cascade that parallels the PKR/eIF-2
cascade
(54). In mouse fibroblasts, PKR and RNase L are solely
required and sufficient for the dsRNA-induced inhibition of
translation, since cells with a combined deficiency in both genes fail
to inhibit translation when challenged with dsRNA (26). We
considered the possibility that RNase L might be involved in mediating
the dsRNA-induced signaling to NF-
B. To test this hypothesis, we
employed 3T3-like fibroblast cell lines with
pkr+/+/rnasel+/+,
pkr+/+/rnasel
/
, and
pkr
/
/rnasel
/
genotypes
(84). Both the cells with a single RNase L deficiency and
the cells with a combined PKR and RNase L deficiency displayed dsRNA-induced degradation of I
B-
in a manner similar to the wild-type cells (Fig. 8, compare lanes 1 to 3 with lanes 4 to 6). Furthermore, in each cell line, NF-
B
translocated to the nucleus in response to dsRNA treatment (Fig.
9). We concluded, therefore, that neither
PKR nor RNase L is a critical component in mediating the dsRNA-induced
signaling to NF-
B.

View larger version (85K):
[in this window]
[in a new window]
|
FIG. 8.
dsRNA-induced degradation of I B- in cells
deficient in RNase L or both RNase L and PKR. 3T3-like fibroblast cell
lines with pkr+/+/rnasel+/+,
pkr+/+/rnasel / , and
pkr / /rnasel / genotypes were
treated with Lipofectin alone (lanes Control) or with pI-pC (10 µg/ml) in the presence of Lipofectin (lanes dsRNA). At the indicated
times after treatment, the cells were harvested and the steady-state
levels of I B- were assessed as in the experiment in Fig. 1A. The
membranes were stripped and reprobed with an anti-PKR antibody
(D-20).
|
|

View larger version (91K):
[in this window]
[in a new window]
|
FIG. 9.
dsRNA-induced nuclear translocation of NF B in cells
deficient in RNase L or both RNase L and PKR. 3T3-like fibroblast cell
lines with pkr+/+/rnasel+/+,
pkr+/+/rnasel / , and
pkr / /rnasel / genotypes were
treated with Lipofectin alone (Control) or with pI-pC (10 µg/ml) in
the presence of Lipofectin (dsRNA). At 3 h after treatment, the
cells were fixed and immunostained with an antibody recognizing the
p65/RelA subunit of NF B as in the experiment in Fig. 3.
|
|
 |
DISCUSSION |
The most important result of this study is the demonstration of a
novel response of cells to viral dsRNA that is independent of the
dsRNA-activated PKR. Surprisingly, we found that this response includes
the dsRNA-induced activation of NF-
B (Fig. 2 to 6, 8, and 9) and the
production of beta ("fibroblast") interferon (Fig. 7A), two
critical components of innate immunity that were previously described
by others to depend, in fibroblasts, on the presence of PKR (11,
76, 79). We argue that the activation of NF-
B by dsRNA does
not require PKR because the following critical steps of activation of
this transcription factor by dsRNA were found to be unimpaired in cells
lacking PKR: (i) the phosphorylation, polyubiquitinylation, and
degradation of I
B (Fig. 2); (ii) the nuclear translocation of
NF-
B (Fig. 4); (iii) the specific DNA-binding activity of NF-
B
(Fig. 6); and (iv) the induction of NF-
B-dependent genes, such as
the genes for beta interferon, IL-6, TNF-
, and IAP-2 (Fig. 7 and
data not shown) (for an extended list of established NF-
B-dependent
genes, see reference 42 and references therein).
Evidence for the existence of previously unsuspected novel cellular
sensors for dsRNA and their implication in the anti-viral response and
postviral immunopathic diseases.
Figure
10 summarizes the model we propose for
the ability of viral dsRNA to trigger both pro- and antiapoptotic
cellular programs. The apoptotic program requires the activities of PKR
and RNase L (see below). Based on our findings that the antiapoptotic
program of innate antiviral immunity (which proceeds through the
activation of NF-
B) is independent of the presence of PKR and RNase
L, we postulate the existence of novel, yet to be identified sensors for dsRNA that are different from PKR and, probably, OAS. It is possible that the same novel dsRNA-sensing machinery also mediates the
virus-induced activation of the SAPK (i.e., JNK and p38 MAP kinase),
since the dsRNA-induced activation of SAPK can also proceed in the
absence of PKR and RNase L (26). The activation of NF-
B is thought to mediate cell survival in response to viral infection (48). The combined activation of SAPK and NF-
B, in
turn, is probably involved in the production of alpha, beta, and omega interferons and other alarmones, including inflammatory mediators such
as IL-6 and TNF-
. Concerning the role of inflammatory cytokines induced by dsRNA, we hypothesize that the PKR-independent,
dsRNA-induced activation of the SAPK- and NF-
B-dependent signal
transduction pathways (which lead to the expression of inflammatory
mediators [reference 26 and this study]) may be an
important contributor not only to the acute inflammation but also to
the chronic inflammation caused by persistent viral infections.
Enteroviruses (such as coxsackievirus, poliovirus, echovirus, EMCV,
and other members of the picornavirus family; for a review, see
reference 47) are known to cause debilitating and
long-lasting postviral immunopathic muscle diseases. For instance, the
coxsackievirus-induced mouse model of inflammatory myopathy is
associated with the presence in the affected muscle of persistent dsRNA
viral sequences (60). Wessely et al. (71)
have used transgenic expression of both the plus and minus strands of a
replication-restricted coxsackievirus genome in the mouse heart to
provide experimental evidence that coxsackievirus dsRNA can cause
dilated cardiomyopathy in the absence of infectious viral progeny.
Heart failure due to dilated cardiomyopathy accounts for ~45% of the
cardiac transplantations performed in the United States
(23). An investigation of the involvement of dsRNA-induced
SAPK- and NF-
B-dependent signal transduction pathways in
virus-induced inflammatory myopathies may therefore have important
therapeutic consequences.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 10.
Model for the diverse actions of viral dsRNA at the
cellular level. See explanations in the text.
|
|
Is there an irreconcilable difference between our finding that PKR
is not required for the dsRNA-induced signaling to NF-
B and
interferon production and the results of others who have reached the
opposite conclusion?
In our opinion, there is not an
irreconcilable difference between our results and those of other
workers (11, 76, 79). The best evidence for this is the
indication (already contained in the work of Yang et al.
76) that PKR is not involved in mediating the innate
immunity to viruses at the level of the organism. In that study, the
authors found that injection of dsRNA peritoneally into either
PKR-containing or PKR-deficient mice induced similar levels of beta
interferon mRNA expression in the spleens of the mice of either
genotype (76). However, we are currently unable to offer
an explanation for the differences between our results and the results
of Williams and coworkers and Karin and coworkers (11, 76,
79) in experiments performed in MEF in vitro.
Still, could PKR, under specific circumstances, play a role in the
activation of NF-
B by viral dsRNA? Several recent reports indicate
that this is possible. It has been discovered that when overexpressed
in cells, PKR has the potential to activate IKK2/
(6, 11,
19). Interestingly, a kinase-deficient mutant of PKR retained
the ability to activate IKK2/
upon overexpression, suggesting that
in this case, PKR exerted a kinase-independent action whose nature is
unknown (6, 11). It remains to be elucidated whether this
phenomenon has biological relevance.
What is the major role of PKR (and of the OAS/RNase L system) in
response to virus infections? Obviously, the most relevant answers to
this question should come from the PKR and RNase L genetic knockouts.
The most profound defects we observed in fibroblasts that are deficient
in PKR, RNase L, or both PKR and RNase L were the reduced ability of
dsRNA to inhibit translation (26) and to trigger apoptosis
(our unpublished observations). These results alone establish both PKR
and OAS/RNase L system as important mediators of the proapoptotic
cellular program in response to virus infections. Additional
confirmation of the proapoptotic role of PKR and RNase L comes from the
attempts of several laboratories to establish cell lines overexpressing
either of these two enzymes. Overexpression of either PKR or RNase L
potentiates apoptosis in response to dsRNA (2, 3, 7, 9,
78). Interestingly, PKR-overexpressing cells are also more
sensitive to the cytotoxic effects of TNF-
(78), an
effect probably resulting from an increased sensitivity to apoptotic
stimuli in the face of compromised sustainability of the process of
protein synthesis. Is the PKR-mediated inhibition of protein synthesis
per se a main cause of PKR-induced apoptosis? Some experimental
evidence suggests that this may be the case. For instance, apoptosis
induced by an overexpression of PKR could be counteracted by the
concomitant overexpression of a nonphosphorylatable form of eIF-2
(20, 53). Furthermore, expression of a mutant form of
eIF-2
that mimics phosphorylated eIF-2
was found to induce
apoptosis by itself (53).
Finally, although the evidence provided in this study does not support
a role for PKR in mediating the expression of NF-
B-dependent genes,
our conclusions should not be interpreted as an attempt to rule out the
possible participation of PKR in signal transduction to the nucleus.
Further studies, especially those using powerful DNA array
technologies, are likely to provide a conclusive answer in the near
future. Furthermore, we have recently reported that the PKR- and RNase
L-mediated inhibition of protein synthesis (but not PKR and RNase L per
se) plays a critical role in the ability of dsRNA to trigger the
activation of JNK (26). This establishes the interesting
possibility that dsRNA-activated JNK may play a role in mediating
dsRNA-induced apoptosis. This possibility is currently being investigated.
 |
ACKNOWLEDGMENTS |
We thank Olga Ryabinina, Thanh-Hoai Dinh, and Paul Spitz for
excellent technical assistance. We thank Bryan Williams for the pkr+/+(EX2+3) and
pkr0/0(EX2+3) MEF and Robert
Silverman for the
rnasel+/+|pkr+/+,
rnasel
/
|pkr+/+, and
rnasel
/
|pkr
/
3T3-like
fibroblasts and for the EMCV.
This work was supported by U.S. Public Health Service grants CA-39360
and ES-08456 to B.E.M. and by an N. L. Tartar Research Fund
Fellowship to M.S.I. J.C.B. is supported by the National Cancer
Institute of Canada and the Canadian Cancer Society.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Cell and Developmental Biology, Oregon Health Sciences University,
Portland, OR 97201. Phone: (503) 494-7811. Fax: (503) 494-4253. E-mail: magunb{at}OHSU.edu.
 |
REFERENCES |
| 1.
|
Abraham, N.,
D. F. Stojdl,
P. I. Duncan,
N. Methot,
T. Ishii,
M. Dube,
B. C. Vanderhyden,
H. L. Atkins,
D. A. Gray,
M. W. McBurney,
A. E. Koromilas,
E. G. Brown,
N. Sonenberg, and J. C. Bell.
1999.
Characterization of transgenic mice with targeted disruption of the catalytic domain of the double-stranded RNA-dependent protein kinase, PKR.
J. Biol. Chem.
274:5953-5962[Abstract/Free Full Text].
|
| 2.
|
Balachandran, S.,
C. N. Kim,
W. C. Yeh,
T. W. Mak,
K. Bhalla, and G. N. Barber.
1998.
Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling.
EMBO J.
17:6888-6902[CrossRef][Medline].
|
| 3.
|
Balachandran, S.,
P. C. Roberts,
T. Kipperman,
K. N. Bhalla,
R. W. Compans,
D. R. Archer, and G. N. Barber.
2000.
Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/caspase-8 death signaling pathway.
J. Virol.
74:1513-1523[Abstract/Free Full Text].
|
| 4.
|
Bender, K.,
M. Gottlicher,
S. Whiteside,
H. J. Rahmsdorf, and P. Herrlich.
1998.
Sequential DNA damage-independent and -dependent activation of NF-kappaB by UV.
EMBO J.
17:5170-5181[CrossRef][Medline].
|
| 5.
|
Birnbaum, M. J.,
R. J. Clem, and L. K. Miller.
1994.
An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs.
J. Virol.
68:2521-2528[Abstract/Free Full Text].
|
| 6.
|
Bonnet, M. C.,
R. Weil,
E. Dam,
A. G. Hovanessian, and E. F. Meurs.
2000.
PKR stimulates NF- B irrespective of its kinase function by interacting with the I B kinase complex.
Mol. Cell. Biol.
20:4532-4542[Abstract/Free Full Text].
|
| 7.
|
Castelli, J.,
K. A. Wood, and R. J. Youle.
1998.
The 2-5A system in viral infection and apoptosis.
Biomed. Pharmacother.
52:386-390[CrossRef][Medline].
|
| 8.
|
Castelli, J. C.,
B. A. Hassel,
A. Maran,
J. Paranjape,
J. A. Hewitt,
X. L. Li,
Y. T. Hsu,
R. H. Silverman, and R. J. Youle.
1998.
The role of 2'-5' oligoadenylate-activated ribonuclease L in apoptosis.
Cell Death Differ.
5:313-320[CrossRef][Medline].
|
| 9.
|
Castelli, J. C.,
B. A. Hassel,
K. A. Wood,
X. L. Li,
K. Amemiya,
M. C. Dalakas,
P. F. Torrence, and R. J. Youle.
1997.
A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system.
J. Exp. Med.
186:967-972[Abstract/Free Full Text].
|
| 10.
|
Chen, C.,
L. C. Edelstein, and C. Gelinas.
2000.
The Rel/NF- B family directly activates expression of the apoptosis inhibitor Bcl-x(L).
Mol. Cell. Biol.
20:2687-2695[Abstract/Free Full Text].
|
| 11.
|
Chu, W. M.,
D. Ostertag,
Z. W. Li,
L. Chang,
Y. Chen,
Y. Hu,
B. Williams,
J. Perrault, and M. Karin.
1999.
JNK2 and IKKbeta are required for activating the innate response to viral infection.
Immunity
11:721-731[CrossRef][Medline].
|
| 12.
|
Chu, Z. L.,
T. A. McKinsey,
L. Liu,
J. J. Gentry,
M. H. Malim, and D. W. Ballard.
1997.
Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control.
Proc. Natl. Acad. Sci. USA
94:10057-10062[Abstract/Free Full Text].
|
| 13.
|
Diaz-Guerra, M.,
C. Rivas, and M. Esteban.
1997.
Activation of the IFN-inducible enzyme RNase L causes apoptosis of animal cells.
Virology
236:354-363[CrossRef][Medline].
|
| 14.
|
DiDonato, J. A.,
M. Hayakawa,
D. M. Rothwarf,
E. Zandi, and M. Karin.
1997.
A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB.
Nature
388:548-554[CrossRef][Medline].
|
| 15.
|
Donze, O.,
J. Dostie, and N. Sonenberg.
1999.
Regulatable expression of the interferon-induced double-stranded RNA dependent protein kinase PKR induces apoptosis and fas receptor expression.
Virology
256:322-329[CrossRef][Medline].
|
| 16.
|
Foster, G. R., and N. B. Finter.
1998.
Are all type I human interferons equivalent?
J. Viral Hepatol.
5:143-152[CrossRef][Medline].
|
| 17.
|
Gagliardini, V.,
P. A. Fernandez,
R. K. Lee,
H. C. Drexler,
R. J. Rotello,
M. C. Fishman, and J. Yuan.
1994.
Prevention of vertebrate neuronal death by the crmA gene.
Science
263:826-828[Abstract/Free Full Text].
|
| 18.
|
Garoufalis, E.,
I. Kwan,
R. Lin,
A. Mustafa,
N. Pepin,
A. Roulston,
J. Lacoste, and J. Hiscott.
1994.
Viral induction of the human beta interferon promoter: modulation of transcription by NF-kappa B/rel proteins and interferon regulatory factors.
J. Virol.
68:4707-4715[Abstract/Free Full Text].
|
| 19.
|
Gil, J.,
J. Alcami, and M. Esteban.
2000.
Activation of NF-kappa B by the dsRNA-dependen |